Skip to main content
main-content

Type 2 diabetes

Feature content

04-24-2019 | Type 2 diabetes | Feature | Article

Young-onset type 2 diabetes: A different process?

Escalating obesity prevalence and severity has led to type 2 diabetes being diagnosed in ever-younger people, including children. medwireNews rounds up the accumulating evidence suggesting a particularly severe diabetes course in these young people.

04-24-2019 | Primary care | Commentary | Article

Diagnosis age matters when it comes to type 2 diabetes

Editorial board member Jay Shubrook explains how the aggressive course of young-onset type 2 diabetes affects clinical decision-making for primary care providers.

04-17-2019 | Nephropathy | Podcast | Article

Nephrologist expert commentary: The CREDENCE trial

Consultant nephrologist Andrew Frankel tells medwireNews about the rationale and key findings of the CREDENCE trial, and discusses the potential benefits of SGLT2 inhibitors beyond type 2 diabetes (9:45).

04-17-2019 | Nephropathy | Podcast | Article

Primary care expert commentary: The CREDENCE trial

General practitioner Kevin Fernando talks to medwireNews about the importance of the CREDENCE trial from a primary care perspective (4:43).

04-15-2019 | Nephropathy | Podcast | Article

Researcher comment: The CREDENCE trial

Lead investigator Vlado Perkovic talks about the main findings from the CREDENCE trial – demonstrating that canagliflozin is associated with a reduced risk for kidney failure and cardiovascular events in people with type 2 diabetes and chronic kidney disease – and discusses how these results will impact clinical practice (6:51).

04-01-2019 | Nutritional management | Practical approach | Article

A practical guide to delivering nutritional advice to people with diabetes

This article aims to offer a practical guide for health professionals who deliver dietary information to people with diabetes.

03-04-2019 | Mental health | Editorial | Article

Diabetes and dementia: Addressing the needs of an overlooked population

Diabetologist Amar Puttanna addresses growing concerns about the rise of dementia in diabetes care and highlights where guidelines, research efforts, and management options are needed to tackle this comorbidity.

02-28-2019 | Insulin | Commentary | Article

The DUNE study: Insulin and inertia in real-world practice

Jay Shubrook comments on the findings of the multinational DUNE study of glycemic target achievement in people with type 2 diabetes taking insulin.

01-30-2019 | Cardiovascular outcomes | Case study | Article

Cardiovascular risk reduction in type 2 diabetes

Pharmacological management of comorbid cardiovascular risk and type 2 diabetes is undergoing a paradigm shift. General practitioner Kevin Fernando puts recommendations from the ADA/EASD into practice in this patient case study.

12-14-2018 | Risk factors | Feature | Article

Sleep duration: Waking up to a major metabolic risk factor

The effect of sleep duration on glucose regulation and cardiometabolic risk is becoming an increasingly high-profile issue. medwireNews takes a look at the latest evidence, which shows the gravity of the problem but also offers some solutions.

12-14-2018 | Sleep apnea | Editorial | Article

Diabetes and obstructive sleep apnea syndrome: Double trouble

Obstructive sleep apnea syndrome is a common and potentially serious comorbidity in people with diabetes and obesity. John Wilding highlights what you need to know about the condition.

12-05-2018 | Diabetes distress | Editorial | Article

Diabetes distress: What’s in a name?

Sanjay Kalra and Psychiatrist Yatan Pal Singh Balhara question whether “diabetes distress” is well understood outside of the diabetes field and consider whether alternative terminology may help to bridge the knowledge gap.

11-28-2018 | SGLT2 inhibitors | Commentary | Article

What can real-world studies really tell us about amputation risk for SGLT2 inhibitors?

John Wilding considers the real-world studies examining the association between SGLT2 inhibitors and amputation risk in patients with type 2 diabetes.

11-28-2018 | SGLT2 inhibitors | At a glance | Article

Real-world studies of SGLT2 inhibition and amputation risk

How many real-world studies have looked at amputation risk in users of SGLT2 inhibitors, and do the findings support or refute the effect found in CANVAS? medwireNews rounds up the research so far.

11-16-2018 | Dapagliflozin | Feature | Video

Researcher comment: DECLARE-TIMI 58

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

11-14-2018 | Cardiovascular outcomes | Editorial | Article

What have I learned from cardiovascular outcome trials?

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future.

11-10-2018 | SGLT2 inhibitors | At a glance | Article

Round-up of the SGLT2 inhibitor CV outcome trials

With DECLARE-TIMI 58 now published, medwireNews rounds up the SGLT2 inhibitor cardiovascular outcome trials so far.

11-10-2018 | Dapagliflozin | Feature | Video

Expert commentary: DECLARE-TIMI 58

Miles Fisher talks to medwireNews about the results of the dapagliflozin cardiovascular outcomes trial DECLARE-TIMI 58.

10-24-2018 | Diabetes distress | Editorial | Article

Feeling stressed out and not meeting goals: A vicious cycle impacting diabetes self-management

Clinical psychologists Diana Naranjo and Korey Hood tackle the negative feedback loops that can develop around diabetes self-management and offer their insights on strategies to identify and address the roots of distress.

09-30-2018 | UKPDS | At a glance | Article

What we learned from the UKPDS

The UKPDS has so far generated an astonishing 93 original research papers. medwireNews​​​​​​​ rounds them up.

image credits